Bibliography
- SIMMONS G, CLAPHAM PR, PICARD L et al.: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 276(5310276–279.
- ••First description of anti-HIV activity ofCCR5 antagonists.
- LE Y, SHEN W, LI B, GONG Wet al.: A new insight into the role of 'old' chemotactic peptide receptors FPR and FPRL1: down-regulation of chemokine receptors CCR5 and CXCR4. Forum (Genova) (1999) 9(4):299–314.
- GABUZDA D, WANG J: Chemokine receptors and mechanisms of cell death in HIV neuropathogenesis. Neurovirol (2000) 6\(supp1.1):S24–32.
- AGRAWAL L, ALKHATIB G: Chemokine receptors: emerging opportunities for new anti-HIV therapies. Expert Opin. Ther. Targets (2001) 5(3):303–326.
- FUJII N, NAKASHIMA H, TAMAMURA H: The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin. Investig. Drugs (2003) 12(2):185–195.
- SHIRAISHI M, ARAMAKI Y, SETO M et al.: Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. Med. Chem. (2000) 43(10):2049–2063.
- •Describes the SAR of TAK-779 and related compounds.
- DORR P, MACARTNEY M, RICKETT G et al: UK-427857, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5. 10th Conference on Remo viruses and Opportunistic Infections, Boston, MA, USA (February 2003).
- •First presented data on UK-427857.
- PALANI A, SHAPIRO S, CLADER JW et al: Discovery of 4- [(Z)- (4-bromopheny1)- (ethoxyimino)methyl]-1'- [ (2, 4-dimethy1-3-pyridinyl)carbony1]-4'-methyl-1,4'-bipiperidine N-oxide (Sch-351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection. Med. Chem. (2001) 44(21):3339–3342.
- •Useful article for defining some of the constraints in this area.
- ESTE JA: Sch-351125 and Sch-350634. Schering-Plough. Carr. Opin. Investig. Drugs (2002) 3(3):379–383.
- FINKE PE, OATES B, MILLS SG et al: Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1- [N-(methyl)-N-(phenylsulfonyl) amino] -2- (phenyl) 4 (4 (N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-l-y1) butanes. Bioorg. Med. Chem. Lett. (2001) 11(18):2475–2479.
- YANG YF, MUKAI T, GAO P et al.: A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Ear: .1 Immunol (2002) 32(8):2124–2132.